Loading candles…
Nureca Ltd, incorporated in 2016 and headquartered in India, operates in the healthcare and wellness industries. The company specializes in home healthcare monitoring and lifestyle products, focusing on chronic disease management and wellness. Offering over 150 healthcare and wellness products, Nureca primarily serves the Indian market through a digital-first approach leveraging e-commerce platforms. Its product range includes home healthcare monitoring devices and lifestyle products under its flagship brand, Dr Trust. Nureca's products comply with international safety standards, including US FDA and CE certifications.
This page is a live market overview for NURECA LIMITED (NURECA) on the NSE. As a listed security, NURECA LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for NURECA before placing trades on tick2trade.
As of the latest feed, NURECA last traded at ₹336 on NSE, down ₹6.35 (1.85%) from the previous close of ₹342.35. Today's session range is ₹336 – ₹345, against a 52-week band of ₹204 – ₹358. Traded volume today stands at 46 shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for NURECA in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether NURECA is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for NURECA LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in NURECA. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated NURECA option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters | 21 Jul 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and other business matters | 29 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and other business matters | 17 Jan 2026 |
| Buyback | To consider buyback for equity shares and other business matters | 28 Nov 2025 |
| Buyback | To consider buyback for equity shares and other business matters | 10 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 15 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and other business matters | 5 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.